Literature DB >> 2558410

Differential immunological response of patients with rheumatoid arthritis towards two different Epstein-Barr virus strains: inhibition of interleukin-1 release by the B95-8, but not the P3HR-1 virus strain.

T Häupl1, G R Burmester, G Hahn, U Feige, C Rordorf-Adam, J R Kalden.   

Abstract

An abnormal immune response towards the Epstein-Barr virus (EBV) has been documented in patients with rheumatoid arthritis (RA). To investigate whether these findings are due to the transformation event caused by EBV, RA blood mononuclear cells and monocyte-enriched preparations were incubated with two different EBV strains: the transforming virus secreted by the cell line B95-8 and the virus released by the P3HR-1 cell line that is not able to transform due to a small deletion in the U2 region of the virus genome. Immunological response was determined by the production of interleukin-1 (IL-1) and tumor necrosis factor (TNF) using ELISA and bioassay systems. There was a striking difference in cytokine measurements with a strong inhibition of IL-1 and TNF production after incubation with the B95-8 virus, but not the P3HR-1 virus. These data indicate that the disturbed reaction of the immune system towards EBV is either dependent on the full transformation of B cells in RA patients or alternatively due to the secretion of a cytokine inhibitor by the B95-8 cell line.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2558410     DOI: 10.1007/BF00271873

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  22 in total

Review 1.  Epstein-Barr virus infection and autoimmunity in rheumatoid arthritis.

Authors:  P Venables
Journal:  Ann Rheum Dis       Date:  1988-04       Impact factor: 19.103

2.  Release of lymphokines after infection with Epstein Barr virus in vitro. II. A monocyte-dependent inhibitor of interleukin 1 downregulates the production of interleukin 2 and interferon-gamma in rheumatoid arthritis.

Authors:  M Lotz; C D Tsoukas; S Fong; C A Dinarello; D A Carson; J H Vaughan
Journal:  J Immunol       Date:  1986-05-15       Impact factor: 5.422

3.  Comparison of Epstein-Barr virus strains of different origin by analysis of the viral DNAs.

Authors:  G W Bornkamm; H Delius; U Zimber; J Hudewentz; M A Epstein
Journal:  J Virol       Date:  1980-09       Impact factor: 5.103

4.  The suppression of Epstein-Barr virus infection in vitro occurs after infection but before transformation of the cell.

Authors:  D A Thorley-Lawson
Journal:  J Immunol       Date:  1980-02       Impact factor: 5.422

5.  Identity of tumour necrosis factor and the macrophage-secreted factor cachectin.

Authors:  B Beutler; D Greenwald; J D Hulmes; M Chang; Y C Pan; J Mathison; R Ulevitch; A Cerami
Journal:  Nature       Date:  1985 Aug 8-14       Impact factor: 49.962

6.  Analysis of the defects responsible for the impaired regulation of EBV-induced B cell proliferation by rheumatoid arthritis lymphocytes. II. Role of monocytes and the increased sensitivity of rheumatoid arthritis lymphocytes to prostaglandin E.

Authors:  F Hasler; H G Bluestein; N J Zvaifler; L B Epstein
Journal:  J Immunol       Date:  1983-08       Impact factor: 5.422

7.  The abnormal cytotoxic T cell response to Epstein-Barr virus in rheumatoid arthritis is correlated with disease activity and occurs in other arthropathies.

Authors:  J S Gaston; A B Rickinson; Q Y Yao; M A Epstein
Journal:  Ann Rheum Dis       Date:  1986-11       Impact factor: 19.103

8.  B cell activation and the establishment of Epstein-Barr virus latency.

Authors:  E A Hurley; D A Thorley-Lawson
Journal:  J Exp Med       Date:  1988-12-01       Impact factor: 14.307

9.  Suppression of in vitro Epstein-Barr virus infection. A new role for adult human T lymphocytes.

Authors:  D A Thorley-Lawson; L Chess; J L Strominger
Journal:  J Exp Med       Date:  1977-08-01       Impact factor: 14.307

10.  Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts.

Authors:  J M Dayer; B Beutler; A Cerami
Journal:  J Exp Med       Date:  1985-12-01       Impact factor: 14.307

View more
  1 in total

1.  Modulation of monocyte activation in patients with rheumatoid arthritis by leukapheresis therapy.

Authors:  G Hahn; B Stuhlmüller; N Hain; J R Kalden; K Pfizenmaier; G R Burmester
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.